Loading company
AIM ImmunoTech Inc.
AIM · NYSE · ·
$0.17-6.3%Sep 29 close
- 1M
- -33.6%
- 6M
- -68.9%
- 1Y
- -75.2%
- 5Y
- -66.3%
AIM · NYSE · ·
$0.17-6.3%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $26K | $25K | +4.00% |
| Profit | -$3.8M | -$2.8M | -35.58% |
| Profit per share | -$0.43 | -$0.05 | -760.00% |
| Free Cash Flow | -$4M | -$3M | -32.14% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
AIM ImmunoTech Inc. has no earnings call transcript available.
“AIM continues to execute a clear and disciplined strategy centered on advancing Ampligen in pancreatic cancer,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from AIM ImmunoTech Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.